From c9c587ac7f592e81110e099c456f092311db0f74 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 7 May 2026 04:24:27 +0000 Subject: [PATCH] vida: extract claims from 2026-05-07-psychiatric-news-apa-glp1-aud-off-label - Source: inbox/queue/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...g-competency-gap-primary-care-psychiatric-monitoring.md | 7 +++++++ ...se-response-data-absent-despite-mechanistic-evidence.md | 7 +++++++ ...-approved-medications-in-comorbid-obesity-population.md | 7 +++++++ .../2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md | 5 ++++- 4 files changed, 25 insertions(+), 1 deletion(-) rename inbox/{queue => archive/health}/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md (97%) diff --git a/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md b/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md index 6b674e6e2..7363624b1 100644 --- a/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md +++ b/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md @@ -31,3 +31,10 @@ The Psychopharmacology Institute — a CME platform for practicing psychiatrists **Source:** Dr. Will Sauvé, Osmind CMO Osmind CMO Dr. Sauvé frames competency gap as existential for psychiatry: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' Identifies specific gap: psychiatrists managing GLP-1-prescribed patients without understanding central mechanisms, dosing nuances, or psychiatric side effects. + + +## Supporting Evidence + +**Source:** Psychiatric News (APA), February 2026 + +APA's Psychiatric News (February 2026) recommends GLP-1 RAs as second-line AUD treatment requiring metabolic comorbidity, despite JAMA Psychiatry 2025 showing 41.1% reduction in heavy drinking days (NNT 4.3) in AUD + obesity population. The conservative framing (second-line, comorbidity required) contrasts with evidence supporting first-line efficacy. Individual psychiatrists prescribing to >60 patients report 60-70% response rates for alcohol and nicotine reduction, but APA-adjacent guidance maintains naltrexone/acamprosate as first-line despite inferior NNT. diff --git a/domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md b/domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md index c7aaf178c..d584a35c0 100644 --- a/domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md +++ b/domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md @@ -24,3 +24,10 @@ This systematic review of 80 RCTs (107,860 participants) plus large cohort studi **Source:** Gill et al., JAMA Psychiatry 2026 MDD trial used oral semaglutide 14mg (therapeutic weight-loss dose range) and showed motivation improvement, contrasting with high-dose anhedonia reports. No dose-response curve was tested within the trial, leaving the therapeutic window undefined despite positive findings. + + +## Supporting Evidence + +**Source:** Psychiatric News (APA), February 2026 + +APA-adjacent guidance (Psychiatric News, February 2026) provides no dose management protocol or psychiatric monitoring recommendations for GLP-1 use in AUD, despite recommending off-label prescribing for metabolically comorbid patients. The guidance focuses solely on efficacy data without engaging with anhedonia risk, dose titration, or psychiatric side effect monitoring. diff --git a/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md b/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md index 08877808a..cc2a527d4 100644 --- a/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md +++ b/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md @@ -25,3 +25,10 @@ The SEMALCO trial (N=108, 26 weeks, double-blind RCT) demonstrated semaglutide 2 **Source:** Osmind clinical article Q1 2026 Osmind states GLP-1s for AUD show 'effect sizes exceeding those historically seen with naltrexone or acamprosate' based on 2025 JAMA Psychiatry trial, confirming superior efficacy claim with specific comparator medications. + + +## Supporting Evidence + +**Source:** Psychiatric News (APA), February 2026 + +APA's Psychiatric News cites the 41.1% reduction in heavy drinking days (NNT 4.3) from JAMA Psychiatry 2025 as key efficacy data, but recommends GLP-1 RAs only as second-line treatment for patients with comorbid metabolic disease who are non-responsive to standard treatments. This creates evidence-to-guideline lag where superior NNT doesn't translate to first-line recommendation. diff --git a/inbox/queue/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md b/inbox/archive/health/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md similarity index 97% rename from inbox/queue/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md rename to inbox/archive/health/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md index d85c68063..4e7f63f07 100644 --- a/inbox/queue/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md +++ b/inbox/archive/health/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md @@ -7,10 +7,13 @@ date: 2026-02-01 domain: health secondary_domains: [] format: article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-07 priority: medium tags: [glp-1, AUD, off-label, psychiatry, APA, prescribing-guidance] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content